Clinical trials: Non-hodgkins Lymphoma
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL).
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT01336933
- Testing
- prednisone, cyclophosphamide, etoposide
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Nebraska
Leukemia, Lymphoma
Resiliency in Older Adults Undergoing Bone Marrow Transplant
The objective of this research is to measure certain indicators of resiliency to better understand which participants who are over 60 years old will respond more positively to bone marrow transplant.
- Conditions
- Leukemia, Lymphoma, Blood Cancer, Myelodysplastic Syndrome
- Trial name
- REBOUND (NCT04188678)
- Testing
- Bone Marrow Transplant (BMT)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HIV-related Lymphoma, HIV Infections
High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk
The purpose of the study is to evaluate the efficacy of an intensified first-line treatment, with conventional chemotherapy (CHOP) plus monoclonal antibody anti CD20, followed by high dose chemotherapy and PBSC transplantation in…
- Trial name
- HDT-HIV (NCT01045889)
- Testing
- Rituximab and CHOP regimen + PBSCT
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Breast Cancer, Non Hodgkin Lymphoma
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
PROACT will establish the effectiveness of the angiotensin-converting enzyme inhibitor (ACEI) enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin lymphoma undergoing adjuvant…
- Trial name
- PROACT (NCT03265574)
- Testing
- Enalapril
- Where
- United Kingdom
- Volunteers
- 111 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard…
- Trial name
- NCT00928018
- Testing
- Sirolimus, Methotrexate, Tacrolimus
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Two Step Haplo With Radiation Conditioning
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma, Aplastic Anemia
- Trial name
- NCT05031897
- Testing
- Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Thomas Jefferson University
Lymphoma
Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vorinostat (MK-0683) in participants with relapsed and/or refractory follicular lymphoma.
- Trial name
- NCT00875056
- Testing
- Vorinostat
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded…
- Conditions
- Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma
- Trial name
- NCT03364231
- Testing
- Umbralisib
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- TG Therapeutics, Inc.
Non Hodgkin Lymphoma
Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL
The purpose of the study is to demonstrate that oral fludarabine phosphate is comparable to i.v. formulation used in combination with mitoxantrone in terms of efficacy, safety and risk/benefit profile
- Trial name
- NCT00185445
- Testing
- Fludarabine Phosphate (Fludara)
- Where
- 14 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Genzyme, a Sanofi Company
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
This phase II trial studies how well ultra low dose orbital radiation therapy works in treating patients with stage I-IV low grade (indolent) B-cell lymphoma or mantle cell lymphoma involving the orbit of the eye (space enclosed…
- Conditions
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma
- Trial name
- NCT02494700
- Testing
- External Beam Radiation Therapy, Orbital Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the safety of JNJ-64264681 at the RP2D(s) in…
- Trial name
- NCT04210219
- Testing
- JNJ-64264681
- Where
- 15 sites in United States, Georgia and 5 more
- Volunteers
- 85 people
- Sponsor
- Janssen Research & Development, LLC
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma.
- Conditions
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT00253630
- Testing
- Laboratory Biomarker Analysis, Vorinostat
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Myeloma, Non Hodgkin's Lymphoma
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers.
- Conditions
- Myeloma, Non Hodgkin's Lymphoma, Leukemia
- Trial name
- NCT07202065
- Testing
- Immune Globulin Intravenous
- Where
- 3 sites in Australia
- Volunteers
- 900 people
- Sponsor
- Monash University
Non-hodgkins Lymphoma
Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma
Current therapies for Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma provide very limited benefit to the patient.
- Trial name
- NCT00003500
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Burzynski Research Institute
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
RATIONALE: Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00962507
- Testing
- everolimus, panobinostat, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Myelodysplastic Syndrome, Hodgkin's Lymphoma
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without a human leukocyte-antigen (HLA) tissue-matched sibling and graft-versus-host disease (GVHD)…
- Conditions
- Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia
- Trial name
- NCT00520130
- Testing
- Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Non Hodgkin Lymphoma (NHL)
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients…
- Trial name
- POTENTIAL-M (NCT07114367)
- Testing
- NB02 (Poseltinib)
- Where
- 6 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- NOBO Medicine
Multiple Myeloma, Non-Hodgkin Lymphoma
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
- Trial name
- NCT04136756
- Testing
- NKTR-255, NKTR-255 Q21, Rituximab
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nektar Therapeutics
B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design.
- Trial name
- NCT04836195
- Testing
- PCLX-001 - 20mg, PCLX-001 - 40mg, PCLX-001 - 70mg
- Where
- 4 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Pacylex Pharmaceuticals
B-cell Non Hodgkin Lymphoma
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL).
- Trial name
- NCT06392477
- Testing
- SAR448501
- Where
- 16 sites in Australia, Serbia and 3 more
- Volunteers
- 96 people
- Sponsor
- Sanofi